Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Renaissance Capital Greenwich Fund (NY: IPOS)
21.57 USD  +0.02 (+0.12%)
Streaming Delayed Price  /  Updated: 7:59 PM EDT, Sep 13, 2019  /  Add to My Watchlist      
View: Quote News
Fund Overview
Renaissance Capital Greenwich Fund
Sector
Exchange Traded NY
Net Assets 2.16M
Inception Date
Related Funds
Quote
Price 21.57
Volume 0
Last Trade Sep 13, 7:59pm
Change (%)
+0.02 (0.12%)
Prev. Close 21.55
YTD %
+15.19%
Dividend Yield 0.97%
Performance
YTD
+2.84 (15.19%)
1 Month
+1.29 (6.39%)
3 Month
+0.55 (2.64%)
6 Month
+0.25 (1.17%)
1 Year
-1.52 (-6.56%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
How Beyond Meat's stock surged 500% in 2019
On its first trading day, Beyond Meat's stock price surged 163%. The hype around the stock continued to push it higher in the following months. Year-to-date returns hit 850% at one point. Here's a look... Read More
from CNBC.com News
J. Crew's Madewell brand files to go public
J. Crew has been reportedly exploring multiple options to turn around its business amid declining sales, including spinning off Madewell. Read More
from CNBC.com News
Top News
More News
Cramer On WeWork IPO: Go Away And Come Back When Things Are Better
Jim Cramer has a simple piece of advice for WeWork ahead of its initial public offering: "Go away." What Happened ... Read More
from Benzinga
SmileDirectClub jumps in second trading day, after disappointing IPO
SmileDirectClub surged more than 11% in midday trading Friday, recovering some losses after the company saw its shares plummet 28% during its disappointing market debut Thursday. Read More
from CNBC.com News
A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga ... Read More
from Benzinga
Cloudflare IPO Opens Above IPO Price
Cloudflare (NYSE: NET) made its public debut Friday morning, opening at $18after being priced at $15per share. The ... Read More
from Benzinga
SpringWorks Opens Above IPO Price
Springworks Therapeutics, Inc. (NASDAQ: SWTX) made its public debut Friday morning, opening at $24.50 after being priced between $16 and ... Read More
from Benzinga
Satsuma Pharma Opens Above IPO Price
Satsuma Pharma(NASDAQ: STSA) made its public debut Friday morning, opening at $19 after being priced in the range of $14-$15 per ... Read More
from Benzinga
'Stop the WeWork deal' — Cramer says the embattled IPO could wreck the stock market rally
WeWork should pull IPO because the negative sentiment around slashing its valuation could be contagious in the overall stock market, says CNBC's Jim Cramer. Read More
from CNBC.com News
WeWork makes sweeping corporate governance changes ahead of IPO
The company is changing its high-vote stock from 20 votes per share to 10 votes per share, curtailing WeWork CEO Adam Neumann's voting power. Read More
from CNBC.com News
WeWork's We Company To List On Nasdaq
WeWork's We Company has filed S-1 paperwork and plans to list on the Nasdaq. We will officially begin marketing the shares to ... Read More
from Benzinga
The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... Read More
from Benzinga
Springworks Therapeutics IPO: What You Need To Know
Another cancer-focused biotech company is readying to tap the public market this week. The IPO Terms Stamford, Connecticut-based ... Read More
from Benzinga
Monopar IPO: What You Need To Know
Cancer is a lucrative area for drug developers, and a company that develops therapies to improve clinical outcome of cancer patients is ... Read More
from Benzinga
Report: AB InBev's Asia IPO Could Still Be Launched
Anheuser Busch Inbev NV (NYSE: BUD) is reconsidering its decision to halt a spin-off of its Asia business, sources close to the matter ... Read More
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.